Here's what Big Pharma could buy in 2025, from obesity drugs to precision cancer treatments, according to a top M&A banker
Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...
Exclusive: Arianna Huffington’s Thrive Global inks novel partnership with pharma giant Eli Lilly
Arianna Huffington's Thrive Global aims to help people build healthy habits. Today, the company announced an exclusive partnership with a Fortune 500 pharma gian ...
FierceBiotech5d
Big Pharma layoff rounds jump 281% in '24, but overall industry rates similar to '23
Overall, biopharma layoffs rose ever so slightly in 2024 compared to the year before, though the number of layoff rounds ...
BioSpace2d
Big Pharma Rushes to China for Deal Prospecting Despite Regulatory Uncertainty
China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.
MM&M5d
Big Pharma hikes prices of 250 drugs in January
Several large drugmakers, including Pfizer, Bristol Myers Squibb and Sanofi, increased the list prices of their drugs this ...
Pharma giant seeks to join lawsuit against FDA over weight loss drugs
Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by ...
Top 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3)
Biotech M&A is heating up, and Mirum Pharmaceuticals stands out. Discover why analysts predict a 50% upside and long-term ...
MM&M2d
Porch Light Health’s multichannel campaign challenges Big Pharma narratives
Developed and launched in just 21 days, Porch Light Health saw an 11% increase in new patients in the first month of the ...
FierceBiotech2d
AbbVie exercises first $40M option to advance Capsida-partnered CNS gene therapy
Gene therapy firm Capsida Biotherapeutics is advancing the first of its AbbVie-partnered neurodegenerative disease therapies ...